Back to top
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. By pressing "Accept All" or closing out of this banner, you accept our Privacy Policy and Terms of Service, revised from time to time, and you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties. You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Image: Bigstock
Chemours (CC) Reports Q4 Earnings: What Key Metrics Have to Say
Chemours (CC - Free Report) reported $1.36 billion in revenue for the quarter ended December 2024, representing a year-over-year decline of 0.2%. EPS of $0.11 for the same period compares to $0.31 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $1.36 billion, representing a surprise of -0.06%. The company delivered an EPS surprise of +10.00%, with the consensus EPS estimate being $0.10.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Chemours performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenues- Other Segment: $13 million compared to the $8.16 million average estimate based on three analysts.
- Revenues- Titanium Technologies: $632 million compared to the $618.85 million average estimate based on three analysts.
- Revenues- Advanced Performance Materials: $324 million compared to the $332.61 million average estimate based on three analysts.
- Revenues- Thermal & Specialized Solutions: $390 million versus $400.22 million estimated by three analysts on average.
- Adjusted EBITDA- Titanium Technologies: $77 million versus the three-analyst average estimate of $69.61 million.
- Adjusted EBITDA- Advanced Performance Materials: $48 million versus $39.15 million estimated by three analysts on average.
- Adjusted EBITDA- Thermal & Specialized Solutions: $123 million versus $111.52 million estimated by three analysts on average.
View all Key Company Metrics for Chemours here>>>Shares of Chemours have returned -13.3% over the past month versus the Zacks S&P 500 composite's +4.7% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.